NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Tuesday that its board of directors has approved a two-for-one split of the firm's common stock, which will take effect next month.

The Salt Lake City-based molecular diagnostics firm said that the split would be effected in the form of a dividend, which is payable on March 25 to shareholders of record at the close of business on March 9. Under the split, shareholders will receive one additional share for each share held.